Amisulpride pharmacokinetics: No difference between young and elderly subjects

I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial

“…It has a very low propensity for drug interactions, 27 being neither a substrate for nor an inhibitor of cytochrome P450 isoenzymes. 28 It can safely be used in elderly individuals, in whom the pharmacokinetic profile matches that in younger adults, 29 and in patients with renal failure, which does increase the plasma concentration 30 but to a modest degree unlikely to represent a clinical issue at the low doses shown to be effective in this trial. This study provides a promising initial indication of efficacy in a typical at-risk surgical population.…”

Selective and sensitive determination of amisulpride in human plasma by liquid chromatography–tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring

“…The peak plasma concentration (C max ) of 522.58 ng/ml, obtained after an oral dose of 200 mg, was higher than theoretically expected under the assumption of linear pharmacokinetics and for healthy volunteers with normal renal function [5]. However, this phenomenon should be discussed carefully since most pharmacokinetic data have been reported for 50 mg dosages so far [3][4][5][6].…”

“…The drug belongs to the so-called atypical antipsychotics and exhibits a dual dopamine receptor-blocking effect at different dose levels [4][5][6]. Low doses of amisulpride are known to block preferentially presynaptic D 2 and D 3 receptors (facilitating dopamine release and enhancing neurotransmission), whereas higher doses block postsynaptic D 2 and D 3 receptors (inhibiting dopaminergic hyperactivity) [3,5].…”